173903-47-4 Usage
Description
Tizoxanide, an active metabolite of the antiparasitic nitazoxanide, is a light yellow powder formed through the deacetylation of nitazoxanide in the stomach. It exhibits potent inhibitory effects against various pathogens, including M. tuberculosis, L. mexicana, T. cruzi, hepatitis B virus, and hepatitis C virus.
Uses
Used in Pharmaceutical Industry:
Tizoxanide is used as an antiviral agent for its potent inhibitory effects on hepatitis B virus and hepatitis C virus replication (EC50 = 0.15 μM for both). This makes it a valuable compound in the development of treatments for these viral infections.
Used in Antituberculosis Applications:
Tizoxanide is used as an antimycobacterial agent for its activity against Mycobacterium tuberculosis (MIC = 16 μg/ml), contributing to the fight against tuberculosis.
Used in Antiparasitic Applications:
Tizoxanide is used as an antiparasitic agent for its ability to reduce the growth of disease-causing parasites L. mexicana and T. cruzi in vitro (IC50s = 6.2 and 17.5 μM, respectively), making it a potential treatment option for parasitic infections.
Used in Antiviral Applications (Influenza A):
Tizoxanide is used as an antiviral agent for its inhibitory effects on influenza A replication (EC50s = 0.3-1 μM), offering potential benefits in the treatment of influenza A infections.
in vitro
previous study found that tizoxanide showed potent inhibition of both hbv and hcv replication. tizoxanide also exhibited selective inhibition of intracellular hbv replication and extracellular virus production by 2.2.15 cells. tizoxanide could selectively reduce intracellular hcv replication in ava5 cells. moreover, the combination of tizoxanide with either recombinant human interferon alpha 2b (ifnα), or an ns5b (hcv polymerase) inhibitor, 2′-c-methyl cytidine, resulted in synergistic interactions against hcv replication. in addition, antiviral activities of tizoxanide against a full-length genotype 1a replicon were equivalent to that observed for ava5 cells [1].
in vivo
animal study in an immunosuppressed rat model suggested that relapses were less frequent after treatment with nitazoxanide, the parent drug of tizoxanide, than with the non-absorbable sinefungin and paromomycin [2].
IC 50
0.17 to 0.21 μm for civs
references
[1] korba be,montero ab,farrar k,gaye k,mukerjee s,ayers ms,rossignol jf. nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis b virus and hepatitis c virus replication. antiviral res.2008 jan;77(1):56-63. [2] gargala g,delaunay a,li x,brasseur p,favennec l,ballet jj. efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against cryptosporidium parvum development in sporozoite-infected hct-8 enterocytic cells. j antimicrob chemother.2000 jul;46(1):57-60.
Check Digit Verification of cas no
The CAS Registry Mumber 173903-47-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,3,9,0 and 3 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 173903-47:
(8*1)+(7*7)+(6*3)+(5*9)+(4*0)+(3*3)+(2*4)+(1*7)=144
144 % 10 = 4
So 173903-47-4 is a valid CAS Registry Number.
173903-47-4Relevant articles and documents
Syntheses and antibacterial activities of tizoxanide, an /V-(Nitrothiazolyl)salicylamide, and its O-aryl glucuronidef
Rossignol, Jean-Francois,Stachulski, Andrew V.
, p. 44 - 45 (1999)
Mild hydrolysis of the broad-spectrum anaerobic antibacterial and antiparasitic agent nitazoxanide 1 affords tizoxanide 2, which is a major metabolite of 1 retaining most of its activity; further metabolism of 2 leads to the 0-aryl glucuronide 3, efficien
Characterization and structural analysis of the potent antiparasitic and antiviral agent tizoxanide
Bruno, Flavia P.,Caira, Mino R.,Martin, Eliseo Ceballos,Monti, Gustavo A.,Sperandeo, Norma R.
, p. 318 - 325 (2013)
Tizoxanide [2-(hydroxy)-N-(5-nitro-2-thiazolyl)benzamide, TIZ] is a new potent anti-infective agent which may enhance current therapies for leishmaniasis, Chagas disease and viral hepatitis. The aim of this study was to identify the conformational prefere
PRODRUGS AND FORMULATIONS THEREOF
-
Page/Page column 32-33, (2021/02/26)
The present invention provides prodrugs and methods of use thereof.
